| Trial ID # | NCT04519151 |
| Phase | II |
| Drug Class | Angiogenesis Inhibitors: Multi-targeted RTK |
| Drug Name | Lenvatinib |
| Alternate Drug Names | MK-7902, Lenvima, ER-203492-00, E7080 |
| Drugs in Trial | Lenvatinib, Pembrolizumab |
| Eligible Participant | Platinum sensitive high grade serous or endometrioid ovarian cancer |
| Patients Enrolled | 24, median 2 prior therapies (1-2), 50% w/ prior bevacizumab |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, DoR, PFS, OS, evaluated per RECIST |
| Efficacy | ORR: 54% (3CR, 10PR) |
| Clinically Significant Adverse Events | Serious AE: |
| Conclusion | The combination of lenvatinib and pembrolizumab shows meaningful responses and manageable toxicity in platinum sensitive recurrent high grade serous OC patients thus potentially provides a non chemotherapy alternative |
| Reference | Bauer S et al. Phase II study of pembrolizumab and lenvatinib in platinum sensitive recurrent ovarian cancer. J Clin Oncol 42, 2024 (suppl 16; abstr 5581) Bauer S et al. Poster |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.